Genscript Biotech Corporation (01548) reported no changes in authorized share capital for October 2025, maintaining a total of 5,000,000,000 ordinary shares at a par value of USD 0.001 each, equivalent to USD 5,000,000 in total authorized share capital.

The company’s issued shares increased by 359,000 during the month, bringing the total from 2,185,319,939 shares to 2,185,678,939 shares. The increase primarily arose from the exercise of share options under the Post-IPO Share Option Scheme, which contributed new shares and raised HKD 2,990,470 in total. At the end of October 2025, 26,611,294 share options remained outstanding under that scheme. No movements were recorded in treasury shares.